News
MSD partners LaNova Medicines on a PD-1 and VEGF targeting candidate for cancer, a potential replacement for its top-seller Keytruda.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback